Does the media favor PACB or AZTA?

In the previous week, Azenta had 1 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 5 mentions for Azenta and 4 mentions for Pacific Biosciences of California. Azenta's average media sentiment score of 0.72 beat Pacific Biosciences of California's score of 0.70 indicating that Azenta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Azenta 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CYRX or PACB?

In the previous week, CryoPort had 1 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 5 mentions for CryoPort and 4 mentions for Pacific Biosciences of California. CryoPort's average media sentiment score of 1.77 beat Pacific Biosciences of California's score of 0.70 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Pacific Biosciences of California 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to MLAB or PACB?

In the previous week, Pacific Biosciences of California had 1 more articles in the media than Mesa Laboratories. MarketBeat recorded 4 mentions for Pacific Biosciences of California and 3 mentions for Mesa Laboratories. Mesa Laboratories' average media sentiment score of 1.20 beat Pacific Biosciences of California's score of 0.70 indicating that Mesa Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesa Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacific Biosciences of California 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, PACB or EVO?

Evotec has higher revenue and earnings than Pacific Biosciences of California. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pacific Biosciences of California $160.01M 2.53 -$546.38M -$0.43 N/A Evotec $891.97M 0.69 -$117.12M N/A N/A

Does the media favor PACB or EVO?

In the previous week, Evotec had 8 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 12 mentions for Evotec and 4 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.70 beat Evotec's score of -0.01 indicating that Pacific Biosciences of California is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 0 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Pacific Biosciences of California (PACB) Competitors

$1.30 +0.03 (+2.36%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$1.31 +0.01 (+0.69%)

As of 09/11/2026 07:37 PM Eastern

Compare

PACB vs. TXG, AZTA, CYRX, MLAB, and EVO

Should you buy Pacific Biosciences of California stock or one of its competitors? Pacific Biosciences of California's main competitors and comparable companies include 10x Genomics (TXG), Azenta (AZTA), CryoPort (CYRX), Mesa Laboratories (MLAB), and Evotec (EVO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Pacific Biosciences of California compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Pacific Biosciences of California (NASDAQ:PACB) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

10x Genomics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

10x Genomics has a net margin of -12.18% compared to Pacific Biosciences of California's net margin of -82.49%. 10x Genomics' return on equity of -9.33% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-12.18%	-9.33%	-7.30%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

10x Genomics currently has a consensus price target of $44.00, indicating a potential downside of 35.85%. Pacific Biosciences of California has a consensus price target of $1.71, indicating a potential upside of 31.73%. Given Pacific Biosciences of California's higher possible upside, analysts plainly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	13.90	-$43.54M	-$0.59	N/A
Pacific Biosciences of California	$160.01M	2.53	-$546.38M	-$0.43	N/A

In the previous week, 10x Genomics had 14 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 18 mentions for 10x Genomics and 4 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.70 beat 10x Genomics' score of 0.66 indicating that Pacific Biosciences of California is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	6 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacific Biosciences of California	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.7% of 10x Genomics shares are held by institutional investors. 8.8% of 10x Genomics shares are held by company insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

10x Genomics beats Pacific Biosciences of California on 11 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Azenta?

Pacific Biosciences of California (NASDAQ:PACB) and Azenta (NASDAQ:AZTA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Azenta has higher revenue and earnings than Pacific Biosciences of California. Azenta is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	2.53	-$546.38M	-$0.43	N/A
Azenta	$593.82M	2.28	-$55.76M	-$2.76	N/A

Pacific Biosciences of California has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market. Comparatively, Azenta has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

Pacific Biosciences of California currently has a consensus price target of $1.71, suggesting a potential upside of 31.73%. Azenta has a consensus price target of $41.20, suggesting a potential upside of 33.55%. Given Azenta's stronger consensus rating and higher probable upside, analysts plainly believe Azenta is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Azenta has a net margin of -20.63% compared to Pacific Biosciences of California's net margin of -82.49%. Azenta's return on equity of 1.18% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%
Azenta	-20.63%	1.18%	0.97%

99.1% of Azenta shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 10.9% of Azenta shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Azenta had 1 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 5 mentions for Azenta and 4 mentions for Pacific Biosciences of California. Azenta's average media sentiment score of 0.72 beat Pacific Biosciences of California's score of 0.70 indicating that Azenta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Azenta	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Azenta beats Pacific Biosciences of California on 12 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

In the previous week, CryoPort had 1 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 5 mentions for CryoPort and 4 mentions for Pacific Biosciences of California. CryoPort's average media sentiment score of 1.77 beat Pacific Biosciences of California's score of 0.70 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Pacific Biosciences of California	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CryoPort has a net margin of -20.05% compared to Pacific Biosciences of California's net margin of -82.49%. CryoPort's return on equity of -7.20% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	-20.05%	-7.20%	-4.30%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

CryoPort currently has a consensus target price of $18.00, indicating a potential upside of 15.76%. Pacific Biosciences of California has a consensus target price of $1.71, indicating a potential upside of 31.73%. Given Pacific Biosciences of California's higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

92.9% of CryoPort shares are owned by institutional investors. 9.5% of CryoPort shares are owned by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

CryoPort has higher revenue and earnings than Pacific Biosciences of California. CryoPort is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$176.18M	4.47	$78.30M	-$0.90	N/A
Pacific Biosciences of California	$160.01M	2.53	-$546.38M	-$0.43	N/A

CryoPort has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.31, suggesting that its stock price is 131% more volatile than the broader market.

Summary

CryoPort beats Pacific Biosciences of California on 12 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Mesa Laboratories?

Mesa Laboratories (NASDAQ:MLAB) and Pacific Biosciences of California (NASDAQ:PACB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Mesa Laboratories currently has a consensus target price of $110.00, indicating a potential downside of 8.99%. Pacific Biosciences of California has a consensus target price of $1.71, indicating a potential upside of 31.73%. Given Pacific Biosciences of California's higher probable upside, analysts plainly believe Pacific Biosciences of California is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83

90.6% of Mesa Laboratories shares are held by institutional investors. 2.8% of Mesa Laboratories shares are held by insiders. Comparatively, 3.7% of Pacific Biosciences of California shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Pacific Biosciences of California had 1 more articles in the media than Mesa Laboratories. MarketBeat recorded 4 mentions for Pacific Biosciences of California and 3 mentions for Mesa Laboratories. Mesa Laboratories' average media sentiment score of 1.20 beat Pacific Biosciences of California's score of 0.70 indicating that Mesa Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesa Laboratories	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pacific Biosciences of California	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mesa Laboratories has a net margin of 1.92% compared to Pacific Biosciences of California's net margin of -82.49%. Mesa Laboratories' return on equity of 22.72% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesa Laboratories	1.92%	22.72%	9.82%
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%

Mesa Laboratories has higher revenue and earnings than Pacific Biosciences of California. Pacific Biosciences of California is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesa Laboratories	$249.13M	2.72	$6.71M	$0.84	143.89
Pacific Biosciences of California	$160.01M	2.53	-$546.38M	-$0.43	N/A

Mesa Laboratories has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market. Comparatively, Pacific Biosciences of California has a beta of 2.31, suggesting that its share price is 131% more volatile than the broader market.

Summary

Mesa Laboratories beats Pacific Biosciences of California on 11 of the 16 factors compared between the two stocks.

How does Pacific Biosciences of California compare to Evotec?

Pacific Biosciences of California (NASDAQ:PACB) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Pacific Biosciences of California has a beta of 2.31, indicating that its share price is 131% more volatile than the broader market. Comparatively, Evotec has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

5.8% of Evotec shares are held by institutional investors. 3.7% of Pacific Biosciences of California shares are held by company insiders. Comparatively, 1.0% of Evotec shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Evotec has higher revenue and earnings than Pacific Biosciences of California.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	2.53	-$546.38M	-$0.43	N/A
Evotec	$891.97M	0.69	-$117.12M	N/A	N/A

In the previous week, Evotec had 8 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 12 mentions for Evotec and 4 mentions for Pacific Biosciences of California. Pacific Biosciences of California's average media sentiment score of 0.70 beat Evotec's score of -0.01 indicating that Pacific Biosciences of California is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	0 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Evotec has a net margin of -26.20% compared to Pacific Biosciences of California's net margin of -82.49%. Evotec's return on equity of -24.93% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-82.49%	-5,752.12%	-19.52%
Evotec	-26.20%	-24.93%	-11.35%

Pacific Biosciences of California presently has a consensus target price of $1.71, suggesting a potential upside of 31.73%. Evotec has a consensus target price of $3.00, suggesting a potential upside of 73.41%. Given Evotec's stronger consensus rating and higher probable upside, analysts plainly believe Evotec is more favorable than Pacific Biosciences of California.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.83
Evotec	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Evotec beats Pacific Biosciences of California on 9 of the 13 factors compared between the two stocks.

Get Pacific Biosciences of California News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PACB vs. The Competition

Export

Metric	Pacific Biosciences of California	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$404.08M	$9.74B	$7.17B	$12.85B
Dividend Yield	N/A	1.47%	2.57%	11.71%
P/E Ratio	-3.02	66.42	274.94	25.33
Price / Sales	2.53	108.69	685.45	111.12
Price / Cash	1.65	26.35	76.65	51.52
Price / Book	65.00	5.28	10.33	6.20
Net Income	-$546.38M	$56.67B	$3.50B	$358.50M
7 Day Performance	-3.70%	-2.15%	-3.32%	-2.35%
1 Month Performance	17.12%	-1.66%	-0.41%	-2.77%
1 Year Performance	11.11%	25.07%	19.21%	7.63%

Pacific Biosciences of California Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PACB Pacific Biosciences of California	2.6996 of 5 stars	$1.30 +2.4%	$1.71 +31.7%	+3.2%	$404.08M	$160.01M	N/A	730	News Coverage Analyst Forecast
TXG 10x Genomics	1.3661 of 5 stars	$62.65 flat	$40.57 -35.2%	+425.2%	$8.16B	$642.82M	N/A	1,240	News Coverage Analyst Forecast Insider Trade
AZTA Azenta	2.502 of 5 stars	$31.33 flat	$41.20 +31.5%	-1.2%	$1.37B	$593.82M	N/A	3,000
CYRX CryoPort	2.6307 of 5 stars	$15.81 flat	$18.00 +13.9%	+64.2%	$800.76M	$176.18M	N/A	1,186	Positive News
MLAB Mesa Laboratories	1.4521 of 5 stars	$127.78 flat	$110.00 -13.9%	+91.6%	$715.04M	$249.13M	152.12	680

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PACB) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pacific Biosciences of California (PACB) Competitors

PACB vs. TXG, AZTA, CYRX, MLAB, and EVO

How does Pacific Biosciences of California compare to 10x Genomics?

Summary

How does Pacific Biosciences of California compare to Azenta?

Summary

How does Pacific Biosciences of California compare to CryoPort?

Summary

How does Pacific Biosciences of California compare to Mesa Laboratories?

Summary

How does Pacific Biosciences of California compare to Evotec?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB vs. The Competition

Pacific Biosciences of California Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pacific Biosciences of California (PACB) Competitors

PACB vs. TXG, AZTA, CYRX, MLAB, and EVO

How does Pacific Biosciences of California compare to 10x Genomics?

Which has more volatility and risk, TXG or PACB?

Is TXG or PACB more profitable?

Do analysts rate TXG or PACB?

Which has stronger valuation and earnings, TXG or PACB?

Does the media refer more to TXG or PACB?

Do institutionals and insiders believe in TXG or PACB?

Summary

How does Pacific Biosciences of California compare to Azenta?

Which has preferable valuation & earnings, PACB or AZTA?

Which has more risk & volatility, PACB or AZTA?

Do analysts rate PACB or AZTA?

Is PACB or AZTA more profitable?

Do insiders and institutionals have more ownership in PACB or AZTA?

Does the media favor PACB or AZTA?

Summary

How does Pacific Biosciences of California compare to CryoPort?

Does the media refer more to CYRX or PACB?

Is CYRX or PACB more profitable?

Do analysts rate CYRX or PACB?

Do insiders and institutionals believe in CYRX or PACB?

Which has higher valuation & earnings, CYRX or PACB?

Which has more volatility and risk, CYRX or PACB?

Summary

How does Pacific Biosciences of California compare to Mesa Laboratories?

Do analysts recommend MLAB or PACB?

Do institutionals and insiders believe in MLAB or PACB?

Does the media refer more to MLAB or PACB?

Is MLAB or PACB more profitable?

Which has stronger earnings & valuation, MLAB or PACB?

Which has more risk and volatility, MLAB or PACB?

Summary

How does Pacific Biosciences of California compare to Evotec?

Which has more risk & volatility, PACB or EVO?

Do institutionals and insiders believe in PACB or EVO?

Which has better earnings & valuation, PACB or EVO?

Does the media favor PACB or EVO?

Is PACB or EVO more profitable?

Do analysts rate PACB or EVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PACB vs. The Competition

Pacific Biosciences of California Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools